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III. ABSTRACT
Background Despite their proven efficacy, Haemophilus influenzae type b (Hib) 
conjugate vaccines are not given to most children in the developing world in the face of 
an estimated global Hib disease burden of nearly 2 million cases per annum. A major 
barrier to the introduction of the vaccine would be overcome by diluting the vaccine 
tenfold in DTP. We report a randomised trial comparing the use of Hib conjugate 
vaccine diluted tenfold in a multidose vial of DTP, with that of the full Hib dose. 
Methods 168 infants were randomized to receive either the full-dose Hib polysaccharide 
tetanus toxoid (PRP-T) conjugate vaccine or a 1 in 10 dilution prepared by reconstituting 
the full dose in a 10-dose DTP vial. Infants were vaccinated at 6, 10 and 14 weeks of age 
and received a full-dose as a test of immunological memory at 9 months of age. Sera 
were collected at each visit and at one week following the booster dose. Serum anti- 
capsular PRP antibody concentrations were measured by ELISA.
Results Following the primary vaccination series, 95% of infants in the full-dose arm and 
94% of infants in the 1/10 dose arm achieved protective anti-PRP IgG antibody 
concentrations of > 1.0 pg/ml. Infants receiving the diluted vaccine had significantly 
higher levels of anti-PRP antibody in response to the booster dose (151.36 pg/ml versus 
68.55 pg/ml, P = 0.009).
Conclusions The 1/10 dose of PRP-T was as immunogenic and safe as the full dose. The 
technique of diluting a single dose of PRP-T in a 10-dose DTP vial could potentially 
allow the widespread introduction of Hib vaccine in resource-poor countries currently 
unable to afford full dose Hib conjugate vaccine.
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1.0 INTRODUCTION
1.1 The Pathogen
Haemophilus influenzae is a small gram-negative, encapsulated bacillus. In vitro growth 
requires the presence of supplementary factors including ‘X-factor’ (haemin) and ‘V- 
factor’ (nicotinamide adenine dinucleotide). Encapsulated strains possess a 
polysaccharide outer capsule, which defines six antigenically and biochemically distinct 
types. In the pre-vaccine era 95% of all invasive disease caused by H. influenzae was due 
to the type b serotype (Hib) (Wenger et al., 1992). Hib is set apart from unencapsulated 
strains and from other capsular serotypes by the presence of a unique polyribosylribitol 
phosphate (PRP) capsule. This capsule endows Hib with singular pathogenic potential 
amongst strains of H. influenzae by inhibiting opsonophagocytosis and promoting 
invasion (Moxon and Murphy, 2000).
The organism is a relatively uncommon colonizer of the upper respiratory tract, with 
nasopharyngeal carriage occurring in 3-5% of children in the pre-vaccine era (Barbour, 
1996). In an infant rat model (Moxon and Anderson, 1979), intranasal inoculation of Hib 
was followed by submucosal and subsequent blood stream invasion within minutes, 
suggesting that the outcome of exposure to Hib (i.e. either colonization or infection) is 
determined soon after contact with the respiratory mucosa.
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The spectrum of invasive disease caused by Hib includes meningitis, pneumonia, 
epiglottitis, cellulitis, bacteraemia without localized disease and septic arthritis. 
Traditionally, meningitis has been thought to account for the largest proportion of 
morbidity due to Hib, however this view has been challenged by data suggesting that, in 
the developing world at least, pneumonia due to Hib may be the predominant clinical 
presentation (Mulholland et al., 1997). The focus in the literature however remains on 
those conditions more confidently ascribed to Hib, where the organism is isolated from a 
sterile body site. Non-encapsulated strains of H. influenzae are responsible for otitis 
media and other mild upper respiratory tract infections. These are not considered further 
here.
Meningitis due to Hib is the most serious acute manifestation. Prior to the introduction of 
vaccination, Hib was the most common cause of childhood meningitis in the developed 
world (Peltola, 2000). It usually affects children less than two years of age and is 
uncommon in adults. Peak attack rates occur at 6-7 months of age. The typical picture 
includes an antecedent upper respiratory tract illness followed by deterioration with the 
development of fever and signs of central nervous system involvement. The onset is 
usually insidious but progression may be fulminant. Complications are common and 
include subdural effusions and the development of permanent sequelae such as 
sensorineural deafness and motor deficit (Broome, 1987).
Epiglottitis is uncommon in the developing world, and presents with a dramatic onset of 
fever, sore throat, dyspnoea, drooling and dysphagia in the older child (2-7 years).
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Cellulitis most frequently occurs on the cheek or in the periorbital region in young 
children and is frequently accompanied by bacteraemia. Amongst children 6-36 months 
of age bacteraemia without localized disease is most commonly caused by Streptococcus 
pneumoniae, with Hib the second most common cause of this syndrome. Septic arthritis 
caused by Hib is common in children less than two years of age. Hib infection is 
uncommon in adult life (Moxon and Murphy, 2000).
Pneumonia due to Hib is an important and often unrecognised childhood infection but 
probably represents the most common presentation of invasive Hib disease in the 
developing world (Peltola, 2000). Ascribing a specific aetiology to lower respiratory tract 
infections is problematic, but studies of lung aspirates from infants with pneumonia 
suggest that Hib pneumonia is far more frequent than previously believed (Greenwood, 
1992).
1.2 Immunity to Hib -  natural and vaccine induced
The observation that invasive disease due to Hib is predominant during the period in 
which maternal antibodies wane and prior to the development of acquired immunity 
suggests that specific antibodies mediate protection against Hib infection. Early work 
showed that the therapeutic administration of serum containing high titres of antibody 
against Hib capsular material enhances the phagocytosis of organisms in the 
cerebrospinal fluid (CSF) (Alexander et al., 1942). In addition, human hyperimmune 
globulin protected Apache infants from invasive Hib infection during infancy (Siber et 
al., 1992).
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Exposure to cross-reactive epitopes (such as those of Escherichia coli K100) during the 
early years of life is thought to stimulate the development of natural immunity to Hib 
infection (Insel and Anderson, 1982). The majority of infants who develop invasive Hib 
infection have very low or undetectable titres of anti-PRP antibodies at the time of 
infection (Kayhty et al., 1981). Development of natural antibody to PRP, the antibody 
response to Hib infection and the antibody response to vaccination with purified Hib 
polysaccharide vaccine are all highly age dependent (Peltola et al., 1977). Young infants 
are unable to mount an effective antibody response to polysaccharide antigens, due to the 
T cell independent nature of these antigens.
T cell independent antigens are usually polysaccharides with multiple, identical, 
repeating epitopes and are common to bacteria. These antigens are internalised but not 
processed by T-cells, and consequently are not presented on the cell surface in the 
context of MHC molecules. The ability of such antigens to elicit an antibody response 
relates to their ability to directly activate B-cells by cross-linking antibody on the B-cell 
surface. Polysaccharide antigens are poorly immunogenic in young children, do not elicit 
the production of memory B-cells and stimulate the production of IgM and IgG2a 
antibodies (Eskola et al., 1993).
The conjugation (covalent linkage) of polysaccharide to a protein promotes antigen 
processing by T-cells and transforms the immune response to a T-cell dependent 
response. The conjugate antigen is immunogenic in infants, elicits a memory response,
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and leads to affinity maturation of antibodies and production of antibodies of the IgGl 
subclass. Protein conjugate technology forms the basis for the development of PRP- 
protein conjugate vaccines (Eskola et al., 1993).
1.2.1 Correlates of protection against invasive Hib disease
Levels of serum anti-PRP antibody are a widely accepted correlate of protection against 
invasive Hib infection. Based largely on passive immunization studies and data from 
polysaccharide vaccine trials, minimum serum concentrations of anti-PRP antibodies that 
afford protection against invasive infection have been estimated. Antibody concentrations 
of >0.15 pg/ml correlate with short-term protection whilst levels of 1 pg/ml are thought 
to be indicative of long-term protection (Kayhty et al., 1983). Total serum antibody levels 
may be measured by Farr-type radioimmunoassay (RIA) (Makela et al., 1977). IgG anti- 
PRP antibodies are measured by enzyme-linked immunosorbent assay (ELISA), which 
has largely replaced the RIA (Sutton et al., 1985).
Whilst antibody levels are useful correlates offering an acceptable surrogate marker of 
protection, care needs to be taken in interpreting antibody levels on their own. Additional 
markers such as the functional activity (avidity (Goldblatt et al., 1998), 
opsonophagocytic activity (Vemacchio et al., 2000)) and local mucosal immunity need to 
be considered. In addition, the ability to mount a rapid anamnestic response to repeat 
exposure to antigen (either in the context of repeat vaccination or natural infection) is 
likely to be critical in affording protection against disease (Granoff and Lucas, 1995). 
This is complicated by further evidence that suggests that the immunological priming of
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infants without the presence of circulating antibody may be insufficient to protect against 
invasive Hib infection (Anderson et al., 2000). It is likely therefore that both circulating 
anti-PRP antibodies as well as the ability to elicit a booster response are critical to 
protection. The broad acceptance of these correlates of protection (serum anti-PRP titres 
and the anamnestic response) permits the initial assessment of vaccines against Hib by 
means of small-scale immunogenicity studies, rather than relying on large, expensive 
trials of vaccine efficacy.
1.3 The global burden of disease in the pre-vaccine era
In the pre-vaccine era, Hib was an important cause of life-threatening infection amongst 
infants worldwide. The burden of disease is most easily determined for those “classical” 
infections in which the organism can be isolated from a normally sterile body site (e.g. 
CSF, blood, joint fluid) and this data are most frequently used when citing the incidence 
of invasive Hib disease.
The incidence of meningitis shows significant geographic and ethnic variation, even in 
the pre-vaccine era (Peltola, 2000). In populations such as native inhabitants of Alaska, 
northern Canada and northern Australia, the annual incidence in children aged 0-4 years 
exceeded 150 per 100 000. In the United States, the annual incidence was approximately 
50 per 100 000, twice the average for pre-vaccination Europe. Little reliable data are 
available for South Africa, however in Cape Town rates per 100 000 children were 112 
and 34 for children <1 year and <5 years of age respectively (Hussey et al., 1994). The 
rate in black children was twice that of white and mixed race children. Mortality patterns
15
mirrored those of overall distribution, with case fatality rates of 5% in developed and 
>30% in developing countries.
Epiglottitis showed an unusual distribution, with peaks in incidence in European 
countries such as Switzerland (30 per 100 000) and Finland (13 per 100 000) in children 
<4 years old. In developing countries there was an inverse trend between meningitis and 
epiglottitis, with epiglottitis virtually absent from Australian Aborigine, Alaskan Inuit 
and African children (Peltola, 2001).
Cumulative averages, including all of the “classical” manifestations, varied from 1100 
per 100 000 children <4 years amongst Australian Aborigines to 41 per 100 000 in 
Europe. In Cape Town the rates were 160 and 47 per 100 000 children <1 year and <5 
years respectively (Hussey et al., 1997).
The incidence of pneumonia caused by Hib in infants is more difficult to establish, due to 
the difficulty in obtaining representative samples for bacteriological culture. A small 
study in Papua New Guinea showed a rate of 2860 per 100 000 in children <4 years 
(Lehmann et ah, 1999). Data from The Gambia showed that H. influenzae was the second 
most common cause of pneumonia, with 75% of strains being type b (Greenwood, 1992). 
In the same country, a Hib conjugate vaccine reduced the incidence of severe childhood 
pneumonia by 21%, suggesting that up to a quarter of all severe childhood pneumonia 
may be due to Hib (Mulholland et ah, 1997). This is of particular importance, since lower
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respiratory tract infections remain the commonest cause of childhood mortality in the 
developing world.
The total number of cases Hib pneumonia worldwide may be 1 650 000 cases per annum 
if the Gambian estimations are correct. This is five times higher than the number of cases 
of Hib meningitis.
The disease burden is most heavy in the countries of the developing world. Based on the 
above data, a conservative estimate would show 2.1 million cases occurring annually in 
the developing world compared with 70 000 cases in the developed world in the pre­
vaccine era (Peltola, 2000).
1.4 Vaccines against Hib
1.4.1 Polysaccharides and conjugates
The first vaccines to come into use against Hib infection consisted of the PRP capsular 
polysaccharide outer coat. These vaccines were shown to have an efficacy of 90% 
amongst children aged 18 to 71 months in Finland (Eskola et al., 1987), but were 
ineffective in younger children (Ward et al., 1990) in Alaska. Despite their shortcomings, 
these vaccines were licensed for use in children in the United States and Canada. The 
advent of conjugate vaccines in the late 1980’s was a major advance. Four different 
protein conjugate vaccines rapidly became available. Diphtheria toxoid conjugate (PRP- 
D; ProHIBit) was followed by mutant diphtheria toxin (PRP-CRM197 or HbOC; 
HibTITER), meningococcal outer membrane protein (PRP-OMP; PedvaxHIB) and
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tetanus toxoid (PRP-T; ActHIB, OmniHIB or Hiberix). The conjugate vaccines differ by 
protein carrier, polysaccharide size, method of chemical conjugation and the ratio of 
polysaccharide to protein. Table 1.1 summarizes the properties of these vaccines.
PRP-D, PRP-CRM197 and PRP-T are given as a primary series of three doses, one to two 
months apart, with or without a booster dose at the age of 12-15 months. The PRP-OMP 
vaccine is given as two doses two months apart with a booster dose at 12-15 months of 
age. The United States Advisory Committee on Immunization Practices (1993) 
recommends primary vaccination at 2, 4 and 6 months of age, whilst South Africa 
follows the World Health Organisation accelerated schedule at 6, 10 and 14 weeks of age. 
The need for booster doses is controversial, with certain countries (such as the United 
States) recommending their use and others (such as the United Kingdom) electing to omit 
a booster dose.
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Table 1.1 Haemophilus influenzae type b conjugate vaccines licensed for use among 
children
Vaccine Trade name 
(manufacturer)
Polysaccharide Linkage Protein carrier
PRP-D ProHIBiT(R)
(Connaught)
Medium 6-carbon Diphtheria toxoid
HbOC HibTITER(R)
(Lederle-Praxis)
Small None CRM 197 (mutant 
Corynebacterium 
diphtheriae 
toxin protein)
PRP-OMP PedvaxHIB(R) 
(Merck Sharp 
and Dohme)
Medium Thioether Neisseria 
meningitidis 
outer membrane 
protein complex
PRP-T ActHIB™
OmniHIB(TM)
(Pasteur
Merieux
Vaccines)
Large 6-carbon Tetanus toxoid
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1.4.2 Immunogenicitv and efficacy of conjugate vaccines
The conjugate vaccines have clearly demonstrated their advantage over simple 
polysaccharide vaccines. They are highly immunogenic in young children, show a 
significant booster effect and are effective in reducing pharyngeal carriage of Hib. These 
vaccines are highly effective in preventing invasive Hib infection from the first months of 
life, with most studies demonstrating protection in excess of 90%. One notable exception 
is a study of PRP-D amongst Alaskan Inuits (a population with a high incidence of 
infection) in which the point estimate of efficacy was 35% (Ward et al., 1990). The same 
vaccine was shown to be 87% effective in Finnish infants (Eskola et al., 1987). 
Interestingly, vaccine immunogenicity was limited in both trials (less than 40% of infants 
achieving titres of greater than 1 pg/ml one month after the third dose). The reasons for 
the differences in efficacy between the two populations is unclear, but may be related to 
the age distribution of disease or the high levels of nasopharyngeal carriage amongst Inuit 
children. The PRP-D vaccine is widely regarded as inferior to the other conjugate 
vaccines and is infrequently used today.
Direct comparison of vaccines is complicated by differing vaccine and phlebotomy 
schedules as well as inter-laboratory variation in anti-PRP assays. There are however a 
number of important generalisations which can be made (Granoff et al., 1992). Firstly, 
the antibody response to PRP-D vaccine is lower than the other conjugate vaccines. 
Secondly, only the PRP-OMP vaccine induces substantial increases in antibody 
concentrations after the first dose, and may therefore be useful in those settings in which 
there is a high incidence of disease during early infancy (e.g., Alaskan Natives). The
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immunogenicity of the PRP-T and PRP-CRM vaccines is generally comparable. Table
1.2 summarises immunogenicity data and Table 1.3 efficacy data from a number of 
clinical trials. Serum anti-PRP levels slowly decline following vaccination with any of 
the conjugate vaccines and are boosted by vaccination with any of the available vaccines 
or with native PRP (Decker et al., 1993).
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Table 1.2 Immunogenicity of three Haemophilus influenzae type b vaccines among
infants. Adapted from (1993).
G eom etr ic  m ean  titre , p g /m L  (%  >1 p g /m L ) *
V a cc in e S tu d y  site B efore
v acc in a tion
A fter  d ose  1 A fter  d ose 2 A fter  dose 3
S tu d y  1 T en n essee
PRP-D 0.07 - 0.08 0.28 (29)
PRP-OMP @ 0.11 0.83 0.84 (50) 1.14(55)
HbOC 0.07 0.09 0.13 3.08 (75)
PRP-T 0.10 0.05 0.30 3.64 (83)
S tu d y  2 A lask a
PRP-D 0.06 (4) 0.04 (2) 0.06(11) 0.55 (45)
PRP-OMP @ 0.16(14) 1.37 (57) 2.71 (79) -
HbOC 0.15 (5) 0.07 (0) 0.59 (43) 13.70 (94)
PRP-T 0.18(13) 0.06 (0) 0.32 (20) 2.46 (78)
S tu d y  3 M in n eso ta /
M isso u ri/
T exas
PRP-OMP @ 0.18 2.69 (80) 4.00 (85) 
5.21 (88)
HbOC 0.17 0.11 0.45 (23) 6.31 (90)
PRP-T 0.25 0.19 1.25 (56) 6.37 (97)
* Measured by radioimmunoassay.
+ In all studies, vaccine was administered at 2,4, and 6 months of age.
& Antibody level after one dose includes data from only one of four data collection sites in Tennessee.
@ Current recommendations require only two doses of PRP-OMP in the primary series. For studies 1 and 
3, three doses were administered.
— Data not available.
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Table 1.3. Efficacy of Haemophilus influenzae type b conjugate vaccines among infants.
Adapted from (1993).
Vaccine Population Design Age (months) % efficacy 
(95% Cl *)
PRP-D Finland Open, randomised 3,4,6 89 (70- 96)
Alaskan Native Placebo-controlled,
randomised
2, 4,6 35 (-57- 73)
PRP-OMP Navajo Placebo-controlled,
Randomised
2,4 93 (53- 98)* 
100 (67-100)&
PRP-CRM California Open, partially 
randomised
2,4,6 100 (67-100)
Finland Open 4,6 97 @
PRP-T California Controlled, randomised 2, 4,6 * *
North Carolina Placebo-controlled 2,4,6 * *
United Kingdom Open, controlled 2,3,4 ++
Finland Historical controls 4,6 ++
* Confidence interval.
+ Includes cases that occurred before 18 months of age.
& Includes cases that occurred before 15 months of age.
@ Confidence intervals not reported.
** Studies evaluating efficacy of PRP-T vaccine in the United States were terminated before completion. 
++ Point estimate and confidence intervals not reported.
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1.4.3 Effect on nasopharyngeal carriage
In addition to their direct effect in reducing the risk of invasive Hib disease, conjugate 
vaccines are also effective in reducing nasopharyngeal carriage of Hib. This may 
contribute significantly to the overall effectiveness of these vaccines. The reduction in 
carriage persists until at least one year of age leading to a reduction in circulating 
pathogen and ‘herd immunity’ within a community (Barbour et al., 1995).
1.4.4 Combination vaccines
The combination of Hib conjugate vaccines with other vaccine components has become a 
popular strategy in order to reduce the number of injections required at each vaccine visit. 
Existing combinations included diphtheria toxoid, tetanus toxoid and whole cell pertussis 
vaccine (DTP) in combination with Hib conjugate. Further developments have included 
the use of acellular pertussis vaccine in the DTP component as well as combinations with 
hepatitis B and, recently, inactivated polio vaccines (Decker, 2001). A discussion of the 
various combination vaccines is beyond the scope of this review, apart from the 
observation that the combination of Hib vaccine with acellular pertussis (DtaP) elicits a 
lower anti-PRP levels when compared with Hib vaccine given alone (Eskola et al., 1999).
1.4.5 Side effects of vaccination
Vaccination is generally well tolerated, with minor side effects including fever, local 
erythema, swelling and tenderness. Less frequent complaints include sleepiness, 
irritability, prolonged crying, loss of appetite, diarrhoea, vomiting and skin rash. Fever (>
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38°C) has been recorded in 7-30% of vaccines and induration in 1-50% of infants 
(Carlsson et al., 1994).
1.4.6 Effectiveness of vaccination of HIV-infected infants
Immune responses in HIV-infected children are significantly lower than in uninfected 
infants. Lower antibody levels (Kale et al., 1995) are reported. A study conducted in 
Soweto estimated the effectiveness of HbOC amongst HIV infected infants to be 50.9% 
compared with 96.5% in uninfected children (Madhi et al., 2002). In addition, three fully 
vaccinated HIV-infected children with antibody levels > 0.15ug/ml developed invasive 
disease, suggesting possible functional impairment of antibody in this group of children.
1.4.7 Impact of conjugate vaccines
The introduction of routine vaccination with Hib conjugate vaccine has had a profound 
and predictable impact on the incidence of invasive Hib disease in the developed world 
with virtual elimination of disease in those countries offering vaccination. In the United 
Kingdom only 84 cases of invasive Hib disease occurred between 1992 and 1998 
compared with an estimated 4803 cases should vaccination not have been introduced 
(Moxon et al., 1999). In addition, there was a 40% reduction in total (all causes) cases of 
bacterial meningitis. This pattern has been repeated wherever vaccination has been 
introduced. Indeed the possibility of elimination of invasive Hib infection in countries 
such as the United States is now being expounded as a real possibility (Santosham, 2000).
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In contrast to the successes achieved in the developed world, little progress has been 
made in extending vaccine coverage to those parts of the world that would benefit most 
from vaccination. In Africa, South Africa, The Gambia and Botswana are alone in 
providing routine Hib vaccination. It has been estimated that less than 2% of invasive Hib 
disease worldwide is prevented by current vaccine coverage (Peltola, 2000). The reasons 
for failure to immunize in the developing world include underestimation of disease, 
vaccine supply and delivery issues and complex vaccine schedules. However, the primary 
reason for not including Hib vaccine is simply one of cost. In South Africa routine 
vaccination with PRP-T combined with DTP (CombAct-HIB) was introduced in June 
1999. The projected costs for Hib vaccine for the country in 2002 are R61 million. This 
represents over 70% of total vaccine costs (R85 million) for South Africa (Personal 
Communication, K. Blackbeard, Pharmaceutical Services, Provincial Administration of 
the Western Cape).
1.4.8 Strategies to improve affordability of Hib vaccine 
Clearly there is an imperative to extend vaccination to the developing world. A 
significant reduction in the cost of vaccine would be a major advance in this regard. Since 
vaccine manufacturers have been unwilling to decrease the price of their product, the 
alternative is to develop cost effective strategies for vaccine use. This may be achieved 
by using less vaccine to vaccinate the same number of children, either by reducing the 
number of doses required or by reducing the amount of vaccine delivered per dose.
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Lagos et al (Lagos et al., 1998) conducted a trial comparing the immunogenicity of two- 
dose and fractional-dose regimens of PRP-CRM197 and PRP-T. Fractional doses of one- 
half or one third of the full-dose were derived by withdrawal of the appropriate fraction 
from a full-dose vial into an insulin syringe. The authors found that anti-PRP levels 
elicited by fractional dose PRP-T and PRP-CRM197 after a primary vaccine series, as well 
as those following boosting with PRP, were equivalent to those induced by the full-dose 
vaccine. Two dose schedules were also acceptable, however the two dose schedule of 
PRP-CRM197 gave the least acceptable response. The findings of another group 
(Fernandez et al., 2000) using the same dilution strategy in the Dominican Republic were 
similarly encouraging. Limitations of these studies included the practical difficulty in 
accurately withdrawing a small volume from a vial of vaccine, separate immunization 
with DTP as well as the danger in extrapolating results from a single batch of vaccine. 
Hussey et al (Hussey et al., 1995) compared the immunogenicity of a lpg dose of PRP- 
OMP (PedvaxHIB, normal dose 15pg PRP) with full-dose HbOC. The proportion of 
children achieving protective anti-PRP concentrations after the primary vaccine series 
was the same in the two groups, with higher geometric mean concentrations in the PRP- 
OMP group.
Romero-Steiner et al (Romero-Steiner et al., 2001) evaluated the functional activity of 
antibodies elicited by fractional-dose (full, one-half or one-third dose) vaccination of 
infants with PRP-T. They performed assays of serum bactericidal activity and IgG avidity 
on serum of infants with anti-PRP IgG titres of 2pg/ml or greater. The fractional dose 
regimens elicited similar functional antibody activities to the full-dose vaccine with the
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exception that the avidity index was significantly higher in the one-third dose group 
compared with the full-dose group.
Other authors have evaluated the immunogenicity of two dose schedules in which the 
first dose of PRP-T was given approximately one month following the first DTP dose 
(Campagne et al., 1998, Guimaraes et al., 2002). This strategy aims to exploit the carrier 
priming elicited by the tetanus toxoid component of DTP which might enhance the 
response to the PRP component. This approach elicits strong anti-PRP responses and 
may represent a useful alternative in areas that are unable to afford the full 3-dose 
regimen. The potential cost saving in this case is only one-third of the total vaccine costs.
1.4.9 The need for further investigation of low-dose Hib vaccine
Whilst the Lagos study represented a novel approach to reducing vaccine costs, several 
important questions remain to be answered. Firstly, is this work reproducible in different 
populations and with different batches of vaccine? Secondly, what is the lowest dose of 
Hib vaccine that is still able to elicit a satisfactory response? Finally, and importantly, is 
there a more practical method for administering low-dose vaccine on a large scale as part 
of a vaccine programme?
The present study aims to address these questions. A novel dilution technique, for point- 
of-delivery dilution of a single dose of PRP-T was developed. This allowed the use of a 
single dose of PRP-T for up to ten infants. Immune responses elicited by vaccination with 
the diluted vaccine were compared with full-dose vaccination.
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2.0 METHODS
We conducted a randomised, controlled trial comparing the immunogenicity of full-dose 
Hib vaccine (PRP-T; ActHIB, Pasteur Merieux Connaught, now Aventis Pasteur, Lyon, 
France) with that of the same vaccine diluted 1 in 10 by reconstitution in a 10-dose DTP 
vial.
This study was conducted as part of a larger study evaluating the immunogenicity of two 
investigational Hib vaccines from other manufacturers as well as the two arms described 
here. The other investigational vaccines were given at doses of 10, 5, 2.5, 1.25 or 0.6 pg. 
(Data not shown here -  analysis and serological assays as yet incomplete). At the time of 
conducting the study, the Expanded Programme on Immunization (EPI) in South Africa 
did not offer Hib vaccination. Enrolment was terminated at the time that Hib vaccination 
was introduced into the routine vaccination schedule in South Africa.
The study was approved by the Committee for Research on Human Subjects of the 
University of the Witwatersrand (M980211) and by the Medicines Control Council of 
South Africa. Written informed consent was obtained from the parent or guardian of each 
child.
2.1 Patients and eligibility
The study was conducted at four routine immunization clinics south of Johannesburg. 
Three clinics were situated in and served informal settlements south of Alberton 
(Zonkizizwe, Khumalo and Mluleki clinics) whilst one clinic in Bedfordview served an
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affluent area with formal housing. These clinics were chosen because of their relatively 
stable communities, excellent records of EPI follow-up as well as established links with 
the local health authorities.
Healthy children aged 6 weeks (+/- 14 days) of age who had no contraindications to 
receiving DTP vaccine were eligible for enrolment. Parents were informed of the study 
by research nursing sisters and asked to read and sign the informed consent. Prior to 
study enrolment, nurses took a medical history and conducted an appropriate physical 
examination to ensure that they met all inclusion criteria and none of the exclusion 
criteria.
2.1.1 Subject eligibility
2.1.1.1 Inclusion criteria
1. Healthy male and female children 6 weeks +/- 14 days of age (defined as 28-56 
days of age) whose parent(s) or guardian(s) agreed to vaccine administration 
following a detailed explanation of the study.
2. Children who completed a physical examination indicating they were in proper 
health for immunization.
3. Children who were expected to be available for the entire study period.
2.1.1.2 Exclusion Criteria
1. Children with known or suspected impairment of immunological function 
(including known HIV-infection) or those receiving immunosuppressive therapy.
2. Children with evolving neurological disorder or history of seizure.
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3. Children with major congenital malformations or serious chronic disorders (e.g. 
Down's syndrome, diabetes, sickle cell anaemia).
4. Children on current antibiotic therapy for acute illness.
5. Children with previous anaphylactic reaction.
6. Children with previous severe vaccine associated adverse reaction.
7. Children with a history of Haemophilus influenzae infection of a normally sterile 
body site (e.g. meningitis, bacteraemia, pneumonia, epiglottitis)
8. Children with history of idiopathic thrombocytopenic purpura
9. Children for whom DTP or oral polio vaccine were contraindicated.
Note: Development of any of these conditions after enrolment resulted in exclusion from 
further doses of vaccine.
The following two conditions were considered temporary or self-limiting 
contraindications to vaccination and a subject was included once these conditions have 
resolved and no other exclusion criteria were met:
1. A current febrile (rectal temperature >38°C) illness or other acute illness.
2. Received any vaccine within the past 4 weeks or gamma globulin within the past 
3 months.
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2.1.2 Withdrawal from the study
The following events occurring after a previous dose of study vaccine warranted 
withdrawal from further doses of study vaccine (these are adverse effects associated with 
the use of pertussis vaccination):
1. Encephalopathy within 7 days of vaccination;
2. A convulsion, with or without fever, occurring within 3 days of vaccination;
3. Persistent, inconsolable screaming or crying for 3 or more hours within 48 hours 
of vaccination;
4. An unusual, high-pitched cry within 48 hours of vaccination;
5. Collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours 
of vaccination;
6. Temperature of greater than or equal to 40.5°C unexplained by another cause, 
within 48 hours of vaccination;
7. An immediate allergic reaction (anaphylaxis)
2.2 Study groups and randomisation
Infants in the two arms reported here were randomised to receive either the full-dose 
PRP-T conjugate vaccine containing lOpg of PRP polysaccharide (ActHIB, Pasteur 
Merieux Connaught (PMC), now Aventis Pasteur, Lyon, France) or a one-in-ten dilution 
in DTP (PMC, Lyon, France) of this vaccine. Children randomised to the other 10 arms 
of the study received one of two investigational Hib vaccines from other manufacturers 
given at doses of 10, 5, 2.5, 1.25 or 0.6 pg. (Data not shown). All children received 
concurrent oral polio vaccine and hepatitis B vaccine. The randomisation scheme was
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generated by a statistician and maintained in confidence from the investigators and from 
the clinical monitors.
2.3 Vaccine formulation and dilution technique
The full-dose vaccine contains 1 Ogig PRP polysaccharide covalently conjugated to 24jig 
tetanus toxoid. The dilution was performed by reconstituting a single dose (0.5ml) of 
lyophilised Hib vaccine with DTP in a ten-dose DTP vial (Figure 1). This was done by 
removing 0.5 ml from the DTP vial, reconstituting the lyophilised Hib with this volume 
and then re-injecting the reconstituted DTP-Hib into the 10-dose DTP vial. The vial was 
inverted several times to mix the contents and a single dose of this vaccine was then used 
for each child (ten doses per vial).
Children receiving the full dose of PRP-T were vaccinated with DTP at a separate site. 
Reconstituted vaccine was kept refrigerated and vaccine remaining at the end of each day 
was discarded. Infants were vaccinated at 6, 10 and 14 weeks of age. A single injection of 
the full-dose Hib vaccine was given as a booster to all children at 9 months of age.
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Figure 2.1 Method of deriving 1/10 dose by dilution in a 10-dose DTP vial
Vaccination 
(10 doses)
2.4 Collection of samples and serologic analysis
Heel-prick blood specimens were collected at each vaccine visit and at 18 weeks of age 
to assess the primary response to vaccination. In addition, specimens were collected at 
the 9-month visit and again one week later to assess the ability of the vaccines to elicit 
immunological memory.
The clotted blood was refrigerated and clarified by centrifugation within 24 hours after 
collection. Serum was stored in a -70°C freezer. Anti-PRP IgG antibodies were measured 
by a standard quantitative enzyme immunoassay (Phipps et al., 1990) modified (Kayhty 
et ah, 1987) using HboHA (NIBSC, Potters Bar, the UK) as antigen. The assays were 
performed on coded samples in a blinded fashion in the Pneumococcal Diseases Research 
Unit, Johannesburg, and whenever possible the sera before and after immunization were 
tested on the same plate. A subset of the same sera was also tested at the National Public 
Health Institute, Finland for quality control.
The primary outcome measures were the proportion of children achieving serum anti- 
PRP concentrations of 0.15pg/ml or greater and lpg/ml or greater following the primary 
vaccine series.
2.5 Recording of adverse events
Following each vaccination, the subject was observed for approximately 30 minutes for 
any immediate significant reactions. Each subject also returned to the clinic at 24 hours 
after each vaccination when their body temperature was recorded as well as the size of
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any induration or redness present at both the DTP and Hib injection sites. Hospital 
admission or any event requiring prescription medications, a physician visit within 7 days 
of vaccination, a hospitalisation at any time during the 8 month study period, or any event 
resulting in study termination at any period during the study was documented.
2.6 Statistical analysis
Data were entered into and analysed using Epilnfo Version 6. Chi-square and Mann- 
Whitney tests were used for comparison of antibody cut points and geometric mean titres, 
respectively. A p-value of < 0.05 was considered statistically significant. Log 
transformed data were used for the calculation of the standard deviations.
Bias was minimised at the assay stage by the blinding of the technologist performing the 
ELISA assays. At the clinic level, due to the dilution technique, clinic sisters could not be 
blinded to vaccine formulation, but were educated as to the importance of the correct 
dilution technique.
36
3.0 RESULTS
3.1 Demographic details
A total of 168 infants were enrolled in these two arms. Of these, 83 received the full-dose 
vaccine whilst 85 received the 1/10 dose. Female children accounted for 55% of the full- 
dose arm and 47% of the 1/10 arm. The median age at enrolment in the full-dose arm was 
47 days (range 26-121) and 46 days in the 1/10 arm (range 18-100). At 18 weeks of age 
61 of those receiving the full-dose and 73 of those receiving the diluted dose were 
available for analysis. At nine months of age, 46 and 56 infants in each group 
respectively received the booster dose of vaccine.
3.2 Immunogenicity analysis
Both vaccine regimens resulted in excellent serological responses (Table 3.1). In both 
vaccine groups 100% of infants achieved anti-PRP responses of >0.15 pg/ml following 
the primary immunization series. In the full dose arm 95% of infants and in the 1/10 dose 
arm 94% of infants achieved responses of > l.Opg/ml Antibody concentrations of >0.15 
pg/ml were maintained by the majority of infants in both groups at the 9-month visit 
(100% in full-dose arm and 98% in diluted-dose arm). There were no significant 
differences between the two groups in the percentage of children achieving antibody 
concentrations >0.15 pg/ml or > 1.0 pg/ml at any time. The loss to follow-up was 
similar in both groups. The geometric mean antibody concentrations after the primary
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series were non-significantly lower in the 1/10 group, but were well above the 0.15 pg/ml 
level.
Both groups showed evidence of immunological memory with significant increases in 
antibody concentrations one week following the 9-month booster dose. In addition, 
amongst the children who completed the study, the mean post-boost antibody 
concentrations were significantly higher (p=0.009) in the group of 49 children who 
received primary immunization with the diluted vaccine (151.36pg/ml) than in the group 
of 41 children who received the full-dose vaccine (68.55pg/ml).
3.3 Adverse events
The incidence of local and systemic adverse reactions was not different between the two 
groups (Table 3.2). Two subjects receiving the diluted vaccine and one receiving the full- 
dose developed mild local induration following vaccination. Four children in the full- 
dose group were admitted to hospital during the course of the study with vaccine- 
unrelated illnesses (dysentery, bronchopneumonia, malnutrition, kwashiorkor) whilst one 
infant in the diluted-dose group was admitted with bronchopneumonia. There were no 
withdrawals from the study for vaccine-related adverse events.
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Table 3.1. Serum PRP antibody concentrations following primary immunization series 
(18 weeks) and before and after booster dose of vaccine (9 months)
Time of measurement of anti - Full-dose PRP-T 1:10 Dilution PRP-T
PRP concentrations
18 weeks of age
Number of infants 
% > 0.15pg/ml (95% Cl)
% > 1 .Opg/ml (95% Cl) 
Geometric mean anti-PRP 
concentrations in pg/ml (95% Cl)
61
100 (9 4 - 100)
95.1 (86.9-98.4) 
19.40(12.90-29.17)
73
100 (9 5 - 100)
94.4 (86.7 -  97.8) 
14.13 (10.02-19.91)
9 months of age (pre-boost)
Number of infants 
%>0.15pg/ml 
% > l.Opg/ml 
Geometric mean anti-PRP 
concentrations in pg/ml
46
97.8 (89.1 -99.6) 
87.0 (89.1 -99.6) 
5.30 (3.30-8.52)
56
100 (93.6- 100) 
78.6 (72.8-92.8) 
3.55 (2.50-5.04)
One week following 
9 month booster
Number of infants 
% > 0.15pg/ml 
% > 1 .Opg/ml 
Geometric mean anti-PRP 
concentrations in pg/ml
41
100 (91.6- 100)
100 (87.7- 100) 
68.53 (44.88-104.17)
49
100 (92.7- 100)
100 (92.7- 100) 
151.28 (94.92-241.04)
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Table 3.2 Summary of adverse events associated with Hib vaccination (all clinic visits).
Number of children experiencing adverse reaction
Full-dose group 1/10 dilution group
Immediate reaction 1* 0
Induration (24 hours) 1 2
Redness (24 hours) 0 0
Tenderness (24 hours) 0 0
Hospital admissions 4& j@
*Infant restless, cried - treated with paracetamol 
&dysentery, bronchopneumonia, malnutrition, kwashiorkor 
® bronchopneumonia
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4.0 DISCUSSION
4.1 Immunogenicity of the full-dose and 1/10 vaccines
4.1.1 Antibody concentrations after the primary vaccine series
The antibody responses achieved by both vaccine arms in this study after the primary 
immunization series were excellent and comparable to the best responses achieved in 
other trials of the immunogenicity of the ActHIB vaccine (Mulholland et al., 1997). More 
than 94% of infants in both groups achieved antibody levels correlating with long-term 
protection against invasive Hib infection. Importantly there was no difference between 
the two groups with respect to the percentage of infants achieving protective levels. 
Whilst the geometric mean concentration (GMC) of antibody after the primary series was 
non-significantly lower in the 1/10 arm, the GMC in this arm (14.13 pg/ml) was far in 
excess of the 1 pg/ml thought to correlate with long-term protection.
4.1.2 Memory responses to booster vaccine
As discussed above, the ability of conjugate vaccines to elicit a booster response to 
subsequent antigenic exposure sets them apart from pure polysaccharide vaccines. Some 
authorities have argued that this ability to prime is as appropriate a marker of protection 
as the concentration of antibody concentration following the primary vaccine series 
(Granoff et al., 1993). We measured antibody levels one week following a 9-month 
booster dose of vaccine as a marker of immunological memory. Both the full-dose and 
1/10 vaccine elicited a significant booster response in 100% of subjects. All the infants in
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both groups achieved protective antibody concentrations of > 1 pg/ml one week 
following a booster dose of vaccine.
Of note was the fact that the booster response in the 1/10 arm was significantly stronger 
than in the full-dose arm (GMCs of 151.28 pg/ml and 68.53 pg/ml respectively).
4.1.3 Possible explanations for the stronger booster response in the 1/10 group
There is accumulating evidence that increasing antigen load of the tetanus toxoid protein 
carrier appears to affect the humoral immune response to both the hapten and protein 
carrier. Dagan et al (Dagan et al., 1998) have shown that infants receiving pneumococcal 
vaccine and Hib vaccine both conjugated to a tetanus toxoid carrier showed significantly 
lower anti-PRP responses than those receiving a pneumococcal vaccine conjugated to 
diphtheria toxoid. Antibody concentrations to the tetanus component were also affected 
adversely with increasing tetanus toxoid content of the co-administered vaccines. 
Similarly, low doses of pneumococcal polysaccharide vaccine conjugated to tetanus 
toxoid induced better booster responses than did higher doses of the same vaccine 
(Ahman et al., 1999).
The reasons for the inhibitory effect of high concentrations of tetanus toxoid are 
incompletely understood, but several explanations have been proposed. It appears that 
development of an immune response against the carrier can interfere with the response to 
the polysaccharide component (Barington et al., 1993). This may be the result of 
dominance of B cell clones specific to the carrier component. Carrier-specific clones are
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present at a much higher frequency than polysaccharide-specific clones, and so the extent 
of the decrease in the response to the polysaccharide will be proportional to the intensity 
of the response to the carrier (Dagan et al., 1998). A second possible explanation is that 
the presence of high concentrations of antibodies to the protein carrier could interfere 
with antigen capture or presentation of the saccharide component(Peeters et al., 1991, 
Ahman et al., 1999). Maternal antibodies to tetanus toxoid have previously been shown to 
interfere with the induction of anti-PRP titres in vaccinated infants(Barington et al.,
1993). Finally, the high dose of tetanus toxoid may induce T cell tolerance during the 
primary series(Ahman et al., 1999).
Whatever, the explanation for the improved booster response of low-dose vaccine, the 
finding carries important implications. Firstly, the co-administration of multiple 
polysaccharide vaccines bearing the same protein carrier may result in reduced antibody 
responses. Secondly, the currently licensed dose of PRP-T conjugate vaccine may be too 
high to elicit an optimal response. Thirdly, the 1/10 vaccine, as used in this study, may 
provide superior immunity to the full-dose vaccine (using the booster response as 
correlate of protection).
These findings extend previous work by showing that a one-in-ten fraction of Hib 
vaccine conjugated to tetanus toxoid (PRP -T, Aventis Pasteur, Lyon, France) is as 
immunogenic as a full dose regimen. Since this finding has to date been restricted to 
vaccines conjugated to tetanus toxoid, the serological response to the dilution of this
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vaccine may therefore not be applicable to similar dilutions of other Hib vaccines, 
particularly those in which tetanus toxoid is not used as the carrier protein.
4.1.4 Effect of Hib vaccine on the immunogenicitv of other vaccine components
As described earlier in this report, the concomitant administration of Hib vaccine together
to the PRP component (Eskola et al., 1999). The same is not true of the combination of 
single-dose DTP containing whole cell pertussis with PRP-T. Miller et al compared 
single injection PRP-T plus DTP vaccine with separate injections of the two vaccines and 
found similar antibody responses to all vaccine components in the two groups (Miller et 
al., 1995). There is no evidence to suggest that the combination used in this study (whole 
cell pertussis was used) should result in reduced antibody responses to the DTP 
component.
Further, the vaccine manufacturer suggests that the lyophilized PRP-T vaccine can be 
reconstituted with single-dose DTP. It is therefore unlikely that the addition of 
lyophilized PRP-T to a 10-dose DTP vial, as described in this study, would result in a 
reduction in the immunogenicity of the DTP component. This was not, however 
specifically tested in this study and should perhaps be formally assessed prior to the 
widespread use of the diluted vaccine.
vaccine has been associated with a reduction in antibody response
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4.2 Safety of the low-dose vaccine
Both vaccines were well tolerated. There were no vaccine related severe adverse events 
in either vaccine group. In addition, minor events (swelling and redness) were uncommon 
and no different between the two groups. Since the low-dose vaccine contains the same 
formulation as the full-dose (albeit in a lower dose) there is no reason to suspect that the 
low-dose should be more likely to cause an increased frequency of adverse events..
Bacterial and viral contamination of multi-dose vials has previously been described, 
including an outbreak of Group A streptococcal and staphylococcal skin sepsis associated 
with multi-dose DTP vaccine (Simon et al., 1993). In the present study, emphasis was 
placed on strict aseptic technique during the dilution process and with each withdrawal 
from the vial. At the time of the study, the use of multi-dose DTP vaccine was routine in 
clinics. There were no cases of local injection-site sepsis in this study. Clearly this issue 
would need to be closely monitored if widespread vaccination using this technique was to 
be introduced.
A further practical point that would need to be addressed, should such a method be used 
on a wider scale outside a study setting, would be the need for clear labeling to 
distinguish the PRP-T-containing DTP vials from those containing DTP only.
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5.0 CONCLUSION
There is an ethical as well as medical imperative to make Hib vaccine available in those 
areas of the world that, despite suffering the highest burden of Hib disease, are currently 
unable to afford vaccine. The method of dilution employed here, using a single dose of 
Hib vaccine reconstituted in a 10-dose DTP vial, is simple and convenient, and it 
provides a practical method for utilising fractionated doses on a large scale. The potential 
ten-fold reduction in vaccine costs brings the cost of Hib conjugate vaccine in line with 
that of other EPI vaccines and within the reach of many developing countries.
Further work is needed to demonstrate the stability of the reconstituted diluted vaccine on 
overnight storage, to reduce wastage, although the availability of up to 10 doses for use in 
a single day is already a significant advance over current practice. Lot consistency 
analyses and further studies in other countries of the immunogenicity of the dilution in 
DTP of this Hib conjugate vaccine are suggested. Finally, although the immunological 
correlates of protection of Hib vaccine are well established, the clinical effectiveness of 
the low-dose vaccine in preventing invasive Hib disease needs to be demonstrated.
Ideally this would take the form of a large randomised, controlled trial but given the cost 
and logistic implications and the doubtful support of vaccine manufacturers for such a 
trial, this is unlikely to be feasible. Alternatively, 1/10 dose vaccine could be introduced 
into an area where the current full-dose vaccine is unaffordable. If good baseline data on 
disease prevalence as well as a sound surveillance system were in place in such an area, 
then the effectiveness of the introduction of 1/10 dose vaccine could be demonstrated.
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The recent focus on vaccine delivery in the developing world and the earmarking of 
funds for this purpose has highlighted the need to expand vaccination coverage to areas 
of the world where vaccine-preventable diseases are still common. The strategy 
employed here provides one potential avenue for the cost-effective deployment of such 
funds.
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